Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer

Published:2016-05 Issue:5 Volume:165 Page:1092-1105
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Wang Weimin,Kryczek Ilona,Dostál Lubomír,Lin Heng,Tan Lijun,Zhao Lili,Lu Fujia,Wei Shuang,Maj Tomasz,Peng Dongjun,He Gong,Vatan Linda,Szeliga Wojciech,Kuick Rork,Kotarski Jan,Tarkowski Rafał,Dou Yali,Rattan Ramandeep,Munkarah Adnan,Liu J. Rebecca,Zou Weiping

Funder

Department of Defense

NIH

Ovarian Cancer Research Fund

Marsha Rivkin Center for Ovarian Cancer Research

NIH Common Funds Project

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference32 articles.

1. Radiotherapy and immune checkpoint blockade: potential interactions and future directions;Binder;Trends Mol. Med.,2015

2. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy;Chen;Met. Based Drugs,2010

3. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2;Cui;Immunity,2013

4. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity;Curiel;Nat. Med.,2003

5. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival;Curiel;Nat. Med.,2004

Cited by 333 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10

2. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma;The Oncologist;2024-09-03

3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

4. Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies;Antioxidants & Redox Signaling;2024-08-01

5. Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospects;Apoptosis;2024-07-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3